Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

You must log in to access content on this page. Or click here to request access.
Life, illuminated.
Advancing fluorescent technology to help improve patient care.

MediBeacon is a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement. The science is complex, but the outcomes are simple to understand. How it works >>

MediBeacon technology is available for preclinical use.
MediBeacon technologies are progressing through clinical trials.*
Focused on Providing Kidney Insights to Clinicians

The MediBeacon Transdermal GFR Measurement System (TGFR) is engineered to allow non-invasive detection of the change in patient levels of a fluorescent GFR tracer agent over time via a sensor placed on the patient’s skin. The rate of decrease in the emitted fluorescence from Lumitrace® is automatically calculated and displayed on the monitor and is intended to provide information regarding the rate of clearance of Lumitrace injection which may be useful in the understanding of kidney function in real-time. The TGFR Monitor displays this information in the form of a transdermal GFR (tGFR).

The MediBeacon TGFR includes, Lumitrace (relmapirazin), a fluorescent GFR tracer agent administered as an IV bolus injection.

The TGFR Sensor measures the intensity of Lumitrace fluorescence 2.5 times per second. The rate of decrease of Lumitrace fluorescence measured on the skin is being shown in clinical studies to be highly correlated with measured GFR (mGFR) as determined via Lumitrace plasma clearance. The primary endpoint of the phase 3 study is focused on showing statistical agreement between tGFR and the mGFR.

The TGFR Monitor displays real-time information regarding the rate of decrease in Lumitrace fluorescence and how this changes over time. The monitoring of tGFR changes may prove clinically useful in the assessment of GFR at the point of care.

During a TGFR monitoring session the TGFR Monitor displays fluorescence data collected by the TGFR Sensor. This data is intended to provide an indication of changes in tGFR over time. The duration of a transdermal GFR monitoring session depends on a patient’s kidney function.

GOAL: tGFR Measurement Across Range of GFR

The MediBeacon Transdermal GFR Measurement System (TGFR) is being studied across a range of GFR levels.

Understanding Renal Function is a Significant Clinical Challenge

The MediBeacon TGFR proposed indications for use include the measurement of Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. The FDA granted the TGFR a Breakthrough Device Designation because better tools are needed for the management of kidney patients. Subsequent to an eventual regulatory approval any improvement in the standard of care would need to be demonstrated in the clinic.

There are no limits to our thinking or what that thinking can accomplish.
Focus areas for
fluorescent agent-
based systems include:

Point of care measurement of renal function **
-Learn More


Point of care gastrointestinal
permeability measurement
-Learn More


Fluorescent agent angiography
-Learn More


Fluorescent tracer agent
use in surgery
-Learn More